DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors

[1]  A. Hartmann,et al.  Hereditäre und nichthereditäre syndromale gastrointestinale Stromatumoren , 2010, Der Pathologe.

[2]  R. West,et al.  DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  C. Bacchi,et al.  Imatinib treatment for gastrointestinal stromal tumour (GIST) , 2009, Journal of cellular and molecular medicine.

[4]  C. Park,et al.  PKC‐theta expression in Ewing sarcoma/primitive neuroectodermal tumour and malignant peripheral nerve sheath tumour , 2009, Histopathology.

[5]  J. Lasota,et al.  DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases , 2009, The American journal of surgical pathology.

[6]  C. Corless,et al.  Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes , 2009, The American journal of surgical pathology.

[7]  M. Pierotti,et al.  PDGFRA Immunostaining Can Help in the Diagnosis of Gastrointestinal Stromal Tumors , 2008, The American journal of surgical pathology.

[8]  Kevin S. Smith,et al.  A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors , 2008, The American journal of surgical pathology.

[9]  W. H. Kim,et al.  Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining , 2007, Journal of Clinical Pathology.

[10]  E. Wardelmann,et al.  Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy , 2007, Virchows Archiv.

[11]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[12]  C. Park,et al.  PKCθ expression in gastrointestinal stromal tumor , 2006, Modern Pathology.

[13]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[14]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[15]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Nakajima,et al.  PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT‐negative tumors , 2005, Pathology international.

[17]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[18]  E. Wardelmann,et al.  PDGFRα‐ and c‐kit‐mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features , 2005 .

[19]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[20]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Fletcher,et al.  Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs) , 2004, Cancer Research.

[22]  C. Ball,et al.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.

[23]  J. Fletcher,et al.  KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.

[24]  A. Hagemeijer,et al.  Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity , 2004, The Journal of pathology.

[25]  M. van Glabbeke,et al.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.

[26]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Katoh,et al.  FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products. , 2003, International journal of oncology.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[30]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[31]  E. Wardelmann,et al.  c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant , 2002, Modern Pathology.

[32]  C. Fletcher,et al.  Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.

[33]  C. Park,et al.  PKCtheta expression in gastrointestinal stromal tumor. , 2006, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  E. Wardelmann,et al.  PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. , 2005, Histopathology.

[35]  J. Fletcher,et al.  Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). , 2004, Cancer research.